Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.